Global Evans Syndrome Market - Industry Trends and Forecast to 2028

Market Analysis and Insights : Global Evans Syndrome Market

The Evans syndrome market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 9.30% in the above-mentioned research forecast period. Ongoing research and products under clinical trials are the factors for the growth of the Evans syndrome market.

For instance,

• Peking Union Medical College Hospital has initiated the clinical trial on the single-dose of anti-CD20 antibody with bortezomib. It is used for the treatment of autoimmune hemolytic anemia or Evans syndrome.
• Peking Union Medical College Hospital has started the clinical trial on the tacrolimus which will be used for the treatment of Evans syndrome, autoimmune cytopenia and autoimmune hemolytic anemia.

Evan syndrome is a kind of rare disease which is characterized by the production of antibodies by the body’s immune system which kills or destroys the red blood cells, white blood cells as well as platelets. This results in lower production of red blood cells that is cytopenia. Evans syndrome is related to the association of autoimmune hemolytic anemia and idiopathic thrombocytopenia purpura. It can be occurred either itself which is known as primary Evans syndrome or due to some other disease which is known as secondary Evans syndrome.

Rise in prevalence of autoimmune disease may drive the Evans syndrome market growth, for instance, according to National Institutes of Health, there are up to 23.5 million that is more than 7% Americans suffering from autoimmune disease. In addition, Evans syndrome cases were increased to 1.8 per million person-years and 21.3 per million persons. Increase in awareness about the autoimmune disease may also drive the Evans syndrome market growth. Recurrence of anemia and thrombocytopenia as well as bleeding and infections may hamper the market growth of Evans syndrome. Side-effects related to the treatment such as use of corticosteroids can lead to high blood pressure, high sugar level and weight gain as well as stem cell transplantation does not work for every patient population and no reports showed that the treatment is effective which may hamper the Evans syndrome market growth.  

Increase in healthcare expenditure and support from the government regarding the research and development are some factors that act as opportunity for the Evans syndrome market growth. The exact reason behind the cause of Evans syndrome is still unknown which act as a challenging factor for the Evans syndrome market growth.   

This Evans syndrome market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the Evans syndrome market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Evans Syndrome Market Scope and Market Size

The Evans syndrome market is segmented on the basis of type, diagnosis, treatment, population type, end-user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the Evans syndrome market is segmented into primary Evans syndrome and secondary Evans syndrome.
• On the basis of diagnosis, the Evans syndrome market is segmented into blood test, bone marrow biopsy, flow cytometry and CT scans. Blood test is further segmented to complete blood count (CBC) and direct antiglobulin test.
• On the basis of treatment, the Evans syndrome market is segmented into corticosteroids, immunosuppressive drugs, monoclonal antibody, blood transfusion, IV immune globulin and stem cell transplantation. Corticosteroids are further segmented to prednisolone. Immunosuppressive drugs are further segmented to 6-mercaptopurine and mycophenolate mofetil. Monoclonal antibody is further segmented to rituximab.
• On the basis of population type, the Evans syndrome market is segmented into adults and children.
• On the basis of end-user, the Evans syndrome market is segmented to research institutes, diagnostic laboratories, hospitals and others.
• On the basis of distribution channel, the Evans syndrome market is segmented into hospitals and others.

Global Evans Syndrome Market Country Level Analysis

Global Evans syndrome market is analysed and market size information is provided by country, type, diagnosis, treatment, population type, end-user and distribution channel as referenced above.

The countries covered in the Evans syndrome market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, America accounts the largest market share because of increase in awareness among the population and rising healthcare expenditure. Europe holds the second largest market share due to support from the government for research and development. Asia-Pacific also shares a market due to increase in patient population related to autoimmune disease and increase in developing healthcare technology.    

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The Evans syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to Evans syndrome market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the Evans syndrome market in the growth period.

Competitive Landscape and Global Evans Syndrome Market Share Analysis

The Evans syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global Evans syndrome market.

The major players covered in the global Evans syndrome market report are Pfizer Inc., Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-60605